![Apellis Pharmaceuticals, Inc. logo](/logos/APLS.webp)
Apellis Pharmaceuticals, Inc.
NASDAQ:APLS
Overview | Financials
Company Name | Apellis Pharmaceuticals, Inc. |
Symbol | APLS |
Currency | USD |
Price | 41.05 |
Market Cap | 4,998,494,300 |
Dividend Yield | 0% |
52-week-range | 33.49 - 73.8 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Cedric Francois M.D., Ph.D. |
Website | https://www.apellis.com |
An error occurred while fetching data.
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA)
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD